Transgene SA

0.7030

23-December-24 10:17:32

15 minutes delayed

Stocks

0.0000

0.00%

Today's range

0.7030 - 0.7030

ISIN

FR0005175080

Source

Cboe

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

09 Apr 2024 10:45:00 By Nasdaq GlobeNewswire
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

27 Mar 2024 11:45:00 By Nasdaq GlobeNewswire
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

27 Mar 2024 11:45:00 By Nasdaq GlobeNewswire
Transgene Announces Upcoming Investor Meetings

18 Mar 2024 11:45:00 By Nasdaq GlobeNewswire
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

06 Mar 2024 00:30:00 By Nasdaq GlobeNewswire
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

05 Mar 2024 00:30:00 By Nasdaq GlobeNewswire
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

22 Jan 2024 10:45:00 By Nasdaq GlobeNewswire
Transgene Announces Financial Calendar for 2024

22 Jan 2024 01:00:00 By Nasdaq GlobeNewswire
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

08 Jan 2024 10:45:00 By Nasdaq GlobeNewswire
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023

04 Jan 2024 10:45:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.